Overview

Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector

Status:
Completed
Trial end date:
2021-01-08
Target enrollment:
Participant gender:
Summary
To compare the plasma concentration (bioavailability) and safety of a single naloxone 5 mg autoinjector intramuscular (IM) injection to a single 2 mg IM injection (an approved safe dose) and to a single 2 mg bolus intravenous (IV) injection (an approved safe dose)
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Naloxone